MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
OABI stock logo

OABI

OmniAb, Inc.

$2.4
0.12
 (5.26%)
Exchange:  NASDAQ
Market Cap:  285.817M
Shares Outstanding:  114.821M
Delayed data
Calculate OABI Intrinsic Value
5-year outlook →
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Biotechnology
   
CEO:  Matthew W. Foehr
Full Time Employees:  114
Address: 
5980 Horton Street
EmeryVille
CA
94608
US
Website:  https://www.omniab.com
OmniAb, Inc. is an American biotechnology firm focused on pioneering therapeutic antibody discovery. The company provides a sophisticated platform that allows its industry partners to access a broad spectrum of antibody repertoires and advanced screening techniques, thereby facilitating the development of next-generation treatments. Central to the OmniAb platform is the unique biological capability of proprietary genetically engineered animals, such as OmniRat, OmniChicken, and OmniMouse. These animals are modified to produce human-sequence antibodies, simplifying the creation of human therapeutic candidates. Additionally, OmniAb offers specialized technologies like OmniFlic (a transgenic rat) and OmniClic (a transgenic chicken), which address the requirements for bispecific antibody applications via a common light chain method, as well as OmniTaur, which leverages the distinct structural properties of cow antibodies for challenging targets. The company was founded in 2012 and is based in Emeryville, California.

Click to read more…

Revenue Segmentation

MARKETSnap

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Login — it's free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2026/05/07 — Q1 quarter 2026

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue34,16426,39118,666
Gross Profit34,16426,391-3,391
EBITDA-49,922-50,919-49,764
Operating Income-69,419-74,502-71,518
Net Income-50,619-62,033-64,779

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets401,985325,558300,914
Total Liabilities87,40037,94033,887
Total Stockholders Equity314,585287,618267,027
Total Debt25,56123,16420,334
Cash and Cash Equivalents16,35827,59825,524

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow2,347-39,664-36,455
Capital Expenditure-1,644-1,875-565
Free Cash Flow703-41,539-37,020
Net Income-50,619-62,033-64,779
Net Change in Cash-17,03211,240-2,074

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Low)90,805.235Full AccessFull AccessFull AccessFull Access
Estimated Revenue (High)152,083.190Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Avg)114,800Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Low)-111,410.203Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (High)-66,520.367Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Avg)-84,097.995Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Low)14,069.149Full AccessFull AccessFull AccessFull Access
Estimated Net Income (High)27,473.534Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Avg)19,317.950Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Low)83,800.718Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (High)140,351.826Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Avg)105,944.579Full AccessFull AccessFull AccessFull Access
Estimated EPS (Avg)0.170Full AccessFull AccessFull AccessFull Access
Estimated EPS (High)0.240Full AccessFull AccessFull AccessFull Access
Estimated EPS (Low)0.120Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated Revenue)2Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated EPS)2Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
34.164M  ?P/S
 (TTM)
: 
10.22
?Net Income
 (TTM)
: 
-50619000  ?P/E
 (TTM)
: 
-5.86
?Enterprise Value
 (TTM)
: 
285.969M  ?EV/FCF
 (TTM)
: 
-10.99
?Dividend Yield
 (TTM)
: 
0  ?Payout Ratio
 (TTM)
: 
0
?ROE
 (TTM)
: 
-0.2  ?ROIC
 (TTM)
: 
-0.2
?Net Debt
 (TTM)
: 
-35542000  ?Debt/Equity
 (TTM)
: 
0.07
?P/B
 (TTM)
: 
1.21  ?Current Ratio
 (TTM)
: 
4.8

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Full Access for high/low estimates and the interactive table.

Forward P/E 1YFull AccessFull AccessFull AccessFull Access
N/AFull AccessFull AccessFull AccessFull Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.

[intrinsic_calculator]

Common questions about OABI valuation

Is OmniAb, Inc. (OABI) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for OmniAb, Inc. (OABI) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is OABI a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether OABI trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is OABI’s P/E ratio?

You can see OABI’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for OABI?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is OABI a good long-term investment?

Whether OABI fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

OABI

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

5.26
MARKETSnap

Trading Metrics:

Open: 2.31   Previous Close: 2.28
Day Low: 2.31   Day High: 2.42
Year Low: 1.3   Year High: 2.79
Price Avg 50: 1.86   Price Avg 200: 1.78
Volume: 387324   Average Volume: 653996

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
Could not create stock discussion for OABI

Relevant news

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlists Watchlists
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read